Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
- Authors:
- USP affiliated authors: TOZATTO, EDUARDO - FCFRP ; ROCHA, ADRIANA - FCFRP ; COELHO, EDUARDO BARBOSA - FMRP ; LANCHOTE, VERA LUCIA - FCFRP ; BENZI, JHOHANN RICHARD DE LIMA - FCFRP
- Unidades: FCFRP; FMRP
- DOI: 10.1002/jcph.1745
- Subjects: FÁRMACOS; HIPERTENSÃO; FARMACOCINÉTICA; ANTIDEPRESSIVOS
- Keywords: Venlafaxine,P-gp; Nifedipine; Pharmacokinetics; Enantiomers; Metabolism
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: The Journal of Clinical Pharmacology
- ISSN: 0091-2700
- Volume/Número/Paginação/Ano: v. 61, n. 3, p. 319-327, 2021
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 27 dez. 2025. -
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745 -
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1002/jcph.1745 -
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1002/jcph.1745 - Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
- Estereosseletividade na farmacocinética da Fluvastatina em pacientes diabéticos-hipercolesterolêmicos
- Stereoselective pharmacokinetics of lercanidipine by liquid chromatography tandem mass spectrometry
- Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers
- Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers
- Development of an enantioselective and biomarker-informed translational population pharmacokinetic/pharmacodynamic model for etodolac
- Enantioselective analysis of etodolac in human plasma by LC–MS/MS: application to clinical pharmacokinetics
- LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses
- Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin
- Lercanidipine-fluvastatin interaction: pharmacokinetics stereoselectivity in experimental study
Informações sobre o DOI: 10.1002/jcph.1745 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003033039.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
